Vanguard slashed the value of its holdings in Indian startup Ola by roughly two-thirds, while Neuberger Berman reduced the worth of its PharmEasy shares by more than 90%. These decisions brought Ola’s valuation down to around US$2.65 billion and PharmEasy’s to about US$550 million.